PERSPECTA

News from every angle

← Back to headlines

Incyte Makes Case for Biotech Growth Against Regeneron

Incyte is positioning itself as a strong contender for biotech growth, making its case against established players like Regeneron.

13 Jul, 17:37 — 13 Jul, 17:37
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual46d ago

Own Regeneron For Biotech Growth? Incyte Is Making Its Case.

Read full article →

Related Stories

Kevin Warsh Signals Cautious Fed Approach Amid Persistent Inflation Concerns

13m ago

Fed Chair Warsh Flags Need for More Rate Hikes as Inflation Lingers

46m ago

Klarna CEO Purchases $10 Million in Company Stock

58m ago

Meta Reaches $18 Billion Settlement Mandating Stricter Child Safety Rules

1h ago